Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

BACKGROUND: Bictegravir (B)/emtricitabine (F)/tenofovir alafenamide (TAF) is guideline-recommended treatment for human immunodeficiency virus type 1 (HIV-1). We evaluated whether people receiving dolutegravir (DTG) plus F/TAF or F/TDF (tenofovir disoproxil fumarate) with viral suppression can switch...

Descripción completa

Detalles Bibliográficos
Autores principales: Sax, Paul E, Rockstroh, Jürgen K, Luetkemeyer, Anne F, Yazdanpanah, Yazdan, Ward, Douglas, Trottier, Benoit, Rieger, Armin, Liu, Hui, Acosta, Rima, Collins, Sean E, Brainard, Diana M, Martin, Hal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Online Only Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282313/
https://www.ncbi.nlm.nih.gov/pubmed/32668455
http://dx.doi.org/10.1093/cid/ciaa988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282313/
https://www.ncbi.nlm.nih.gov/pubmed/32668455
http://dx.doi.org/10.1093/cid/ciaa988

Ejemplares similares